To determine the effect of oral glutamine feeding on lymphocyte subpopulations and glutathione metabolism in Peyer's patches (PPs) of healthy and endotoxemic mice.
Objective
To determine the effect of oral glutamine feeding on lymphocyte subpopulations and glutathione metabolism in Peyer's patches (PPs) of healthy and endotoxemic mice.
Summary Background Data
Recent data indicate that nutrients both maintain nitrogen and energy balances and modulate cell and organ function. In particular, glutamine has an impact on gut and immune function. This is of special importance in the perioperative phase.
Methods
Female Balb/c mice were fed a glutamine-enriched diet or a control diet for 10 days. On day 7 25 g lipopolysaccharide (LPS) or saline was injected. On day 3 after the challenge, mice were killed, total cell yield was determined, and lymphocyte subpopulations (total T cells, CD4ϩ, CD8ϩ cells, and B cells) were analyzed by flow cytometry. One experimental group was treated with buthionine sulfoximine, a specific inhibitor of glutathione synthesis. The glutathione content in PPs was measured by high-performance liquid chromatography.
Results
Glutamine administration led to a significant increase in total cell yield, including T and B cells, in PPs. The LPS-induced reduction of T cells (Ϫ45%) and of B cells (Ϫ30%) was significantly lower in glutamine-treated mice. Endotoxemia caused a 42% decrease of glutathione in control animals, but not in glutamine-treated animals. As with LPS, buthionine sulfoximine also lowered lymphocyte numbers and glutathione content of the PPs.
Conclusions
Administration of glutamine prevents LPS-stimulated lymphocyte atrophy in PPs, possibly by increasing the glutathione content in the PPs. Therefore, oral glutamine supply seems to be a suitable approach for improving intestinal immunity in immunocompromised patients.
Several studies have shown decreased extra-and intracellular concentrations of glutamine after surgery, trauma, and burns as well as during sepsis. 1, 2 Because glutamine serves as a precursor of nucleotide synthesis and as an important energy substrate for rapidly dividing cells and because it also supports T-cell and killer cell functions, limited availability of free glutamine has been implicated as a cause of immune dysfunction. [3] [4] [5] [6] Clinical studies have revealed that both parenteral and enteral glutamine supplementation is beneficial in patients after bone marrow transplantation, 7 multiple trauma, 8 critical illness, 9 and surgery. 10 Clinical data are supported by experimental data showing that glutamine administration maintains gut barrier function. 11 Evidence is accumulating that the gut plays an important role in the development of multiple organ failure under septic conditions. Further, it has been proposed that the gut barrier plays a crucial role in systemic inflammatory response, and that the optimal function of the gut-associated lymphoid tissue (GALT) is of utmost importance. The GALT comprises Peyer's Patches (PPs), the appendix, and solitary lymphoid follicles scattered throughout the intestinal mucosa. PPs have attracted special interest because in this intestinal lymphoid organ, B and T cells are primed against intestinal antigens and subsequently seeded as memory or effector cells to distant mucosal effector sites, such as the gut lamina propria. 12 Recently we showed that challenging mice with lipopolysaccharide (LPS) causes the same atrophy of PPs 13 as is found in protein malnutrition. 14 In contrast, Kudsk et al enhanced local GALT by stimulating the enteric nervous system with bombesin 15 and by parenteral administration of glutamine. 16 Enterally provided glutamine stimulates the gut glutathione synthesis. 17 Recently the importance of glutathione, a cysteine-containing tripeptide (L-␥-glutamyl-L-cysteinylglycine), on immune function has been recognized. In vitro experiments revealed that increased cellular glutathione levels were associated with an elevated mitogenic response as well as increased interleukin-2 production. 18 Moreover, glutathione depletion in rats decreased mitogen-stimulated lymphocyte proliferation and reduced tumor necrosis factor-␣ and interleukin-6 secretion by splenic adherent cells. 19 The aim of the present work was to investigate whether pretreatment with oral glutamine has an impact on the intestinal immunity of endotoxin-boostered mice. We hypothesized that glutamine feeding may substantially influence glutathione metabolism, thereby improving the lymphocyte physiology of PPs.
METHODS

Mice Feeding
Female Balb/c mice age 6 to 8 weeks, weighing 15 to 20 g, were obtained from Forschungsinstitut für Versuchstierzucht und haltung (Himberg, Austria). The mice in the investigation group were stratified for their entrance weight. They were pair-fed for 10 days with isocaloric, isonitrogenous diets based on whey protein (Fresenius-Kabi, Bad Homburg, Germany), a control diet (0.5 g glutamine/100 kcal), or a glutamine-enriched diet (3 g/100 kcal). The glutamine dosage given is equivalent to a daily administration of 60 g glutamine for a patient with a body weight of 70 kg. The diets were given in form of pellets. We performed daily measurements of body weight during the study. On day 7 the mice were challenged intraperitoneally with 25 g LPS from Escherichia coli serotype 0127:B8 (Sigma Chemical, St. Louis, MO) or physiologic saline (Fig. 1) . This study was carried out in accordance with National Institutes of Health guidelines on the use of laboratory animals and with the approval of the institutional committee overseeing experimentation on animals.
Buthionine Sulfoximine Treatment
To investigate the impact of glutathione on lymphocyte physiology in PPs, we administered buthionine sulfoximine (BSO; Sigma Chemical), a specific inhibitor of ␥-glutamylcysteine-synthetase, and the key enzyme in glutathione synthesis. During a period of 10 days, glutamine-fed animals received 60 mg/day BSO given intraperitoneally to deplete glutathione.
Isolation of Lymphocytes
PPs were excised from mice killed by cervical dislocation 72 hours after the challenge and were placed into petri dishes on ice and covered with complete medium RPMI-1640 (BioWhittaker, Verviers, Belgium) containing 10% fetal calf serum (Life Technologies, Paisley, Scotland), 2 mmol/L glutamine (Merck, Darmstadt, Germany), 100 U/mL penicillin, and 100 g/mL streptomycin (HyClone Laboratories Inc., Logan, UT). To obtain a single cell suspension, PPs were digested with type 1 collagenase (50 U/mL; Worthington Biochemical Corp., Lakewood, NJ), dissolved in washing medium (RPMI-1640, 5% fetal calf serum, 2 mmol/L glutamine, 100 U/mL penicillin, 100 g/mL streptomycin), and incubated at 37°C for 30 minutes. After collagenase digestion, PPs were passed through a 75-m nylon sieve (Becton Dickinson, Hamburg, Germany), cells were washed twice with washing medium, and viability was assessed by trypan blue exclusion.
Immunofluorescence and FACS Analysis
Total cell count was determined with a hemocytometer. B cells, T cells, T-helper, and T-suppressor/cytotoxic cells were analyzed for cell surface antigen expression. Cells (5 ϫ 10 5 ) were incubated with either isotypic control or monoclonal antibodies against CD3, CD19, CD4, and CD8 (BioTrade, Vienna, Austria) for 30 minutes on ice in the dark. All monoclonal antibodies were conjugated with either fluorescein isothiocyanate (FITC) or phycoerythin. After incubation, cells were washed twice with cold Hank's balanced salt solution (BioWhittaker), and antigen expression was measured by flow cytometry (FACS-EPICS, Coulter, Miami, FL). The total number of lymphocytes was calculated by multiplication of the cell ratio with the total cell count. 
Glutathione
The small intestine was removed and PPs were excised on ice and immediately frozen in liquid nitrogen. For glutathione determination, PPs were homogenized with 6.5% (w/v) sulfosalicylic acid solution (Sigma Chemical). The pH of the supernatant was adjusted to neutrality with NaHCO 3 (Sigma Chemical) and derivatized directly with monobromobimane (Sigma Chemical). Aliquots of the derivatized samples were applied to the high-performance liquid chromatography (HPLC) column to determine thiolbimane adducts. The HPLC separation of thiol-bimane adducts was achieved on a Supelcosil LC-18T octadecylsilyl silica column (125 ϫ 5 mm ID, 3-m particle size) (Supelco Inc., Bellefonte, PA) reversed-phase resin, followed by fluorometric detection at an excitation wavelength of 394 nm and an emission wavelength of 480 nm. Elution solvent A was 9% (v/v) aqueous acetonitrile containing 0.25% (v/v) perchloric acid and 0.25% (v/v) acetic acid; elution solvent B was 75% (v/v) aqueous acetonitrile. 20 
Statistical Analysis
All data are expressed as mean Ϯ standard deviation. The differences between groups were analyzed by the post-hoc test (one-way analysis of variance). Data analysis was performed using the SPSS software package (SPSS for Windows, Release 8.0.0, Chicago, IL). Differences were considered significant at P Ͻ .05.
RESULTS
Body Weight
LPS administration caused a 7% decrease in body weight after 24 hours; weight returned to normal levels after 3 days. All experimental groups were pair-fed, and there was no difference in body weight between groups (data not shown).
Total Cell Yield in PPs
As shown in Figure 2 , LPS injection caused a significant decrease in total cell yield in the control group (Ϫ42%, P Ͻ .001). Oral feeding with glutamine increased total cell yield in healthy (ϩ42%, P Ͻ .01) and in LPS-boostered mice (ϩ100%, P Ͻ .001). Therefore, glutamine feeding diminished the atrophy of PPs after LPS challenge.
Lymphocyte Subpopulations in PPs
In control mice, LPS administration caused a 30% decrease in B cells (P Ͻ .05). Glutamine led to a significantly greater number of B cells in healthy (ϩ41%, P Ͻ .01) and in LPS-boostered mice (ϩ82%, P Ͻ .001) and prevented the LPS-induced B-cell decrease (Fig. 3) .
Similar to B cells, LPS caused a 45% decrease of total T cells in control animals (P Ͻ .01), which was prevented by glutamine prefeeding. The glutamine-fed mice had significantly greater total T-cell numbers in PPs compared with control-fed healthy mice (P Ͻ .01) as well as LPS-boostered mice (P Ͻ .001) (Fig. 4) . Of the measured subpopulations, , GLN ϩ LPS; n ϭ 5) fed the respective diets. Data are expressed as mean Ϯ SD. **P Ͻ .01 vs. control group. Both GLN groups had significantly more total T cells than control-fed animals (P Ͻ .01 GLN vs. control; P Ͻ .001 GLN ϩ LPS vs. control ϩ LPS).
CD4ϩ and CD8ϩ were reduced after LPS administration in the control group (P Ͻ .05) but remained unchanged in the glutamine-fed animals. The CD4/CD8 ratio did not change in either of the experimental groups (Table 1) .
Glutathione in PPs
LPS caused a depletion of glutathione in PPs (Ϫ42%, P Ͻ .001) that was prevented by glutamine administration. The glutathione content of PPs in healthy animals was unaffected by glutamine feeding (Fig. 5) .
Inhibition of glutathione synthesis with BSO significantly diminished glutathione in PPs from 3.4 Ϯ 0.2 nmol/mg wet weight to 1.8 Ϯ 0.3 nmol/mg wet weight (P Ͻ .001). This decrease in glutathione was paralleled by a decrease in total cell yield (10.7 Ϯ 1.1 ϫ 10 6 vs. 4 Ϯ 0.9 ϫ 10 6 , P Ͻ .001). Interestingly, the effect of BSO on B cells was more pronounced than on T cells (B cells Ϫ74%, T cells Ϫ40%) (Fig. 6) . BSO treatment decreased CD4ϩ and CD8ϩ cells in PPs (P Ͻ .001) but did not affect the CD4/CD8 ratio (see Table 1 ).
DISCUSSION
Our results show that oral glutamine administration improves the gut immune system by increasing the number of lymphocytes in PPs and by preventing lymphocyte atrophy of PPs after an endotoxin challenge. The maintenance of PP lymphocytes seems to be associated with a stimulating effect of glutamine on glutathione levels. This study focused on the effect of oral glutamine feeding on lymphocyte physiology of the PPs, an important part of the mucosal immune system. Mucosa-associated lymphoid tissue (MALT) is sensitive to alterations in nutritional substrate supply. Protein malnutrition, 14 but also parenteral feeding, caused a significant drop in the lymphocyte subpopulation in the MALT, which was associated with lowered intestinal IgA levels. Kudsk et al 21 presented evidence that alterations in the mucosal immune system are closely associated with the route of nutrition. Total parenteral nutrition in contrast to enteral nutrition impairs MALT. When parenteral nutrition is supplemented with glutamine, depletion of intestinal lymphocytes was prevented and the intestinal IgA levels were normalized. 17, 22 Moreover, glutaminesupplemented parenteral nutrition protected against bacterial translocation from the gut. 23 Not only nutrition but also pathophysiology affects the intestinal immune system. Deitch et al 24 showed that a combination of nutritional depletion and endotoxemia led to potentiation of immunosuppression in mice. Protein malnutrition decreased the mitogenic response of splenic and mesenterial lymph nodes and PP lymphocytes, which was further reduced by additional LPS boostering of the proteinmalnourished mice. Xin Xu et al 25 showed that hemorrhage led to increased apoptosis in PPs that was associated with elevated Fas expression. We presented evidence that boostering mice with LPS led to a sharp decrease in lymphocyte numbers in PPs 24 hours as well as 72 hours after the challenge. This decrease in lymphocytes was associated Data are expressed as mean Ϯ SD. ***P Ͻ .001 vs. control group. GSH content in the GLN ϩ LPS group was significantly higher than in the control ϩ LPS group (P Ͻ .001). 
with a stimulation of apoptosis and an alteration of the costimulatory signals in the PPs. 13 Interestingly, administration of glutamine before LPS challenge in the current study increased lymphocyte numbers in the PPs and prevented the LPS-evoked lymphocyte decrease in the PPs.
Extensive in vitro studies have revealed that glutamine has a proliferative effect on lymphocytes. 3 Glutamine is required for the activation of T cells, possibly because it stimulates the entry into cell cycle and the expression of "late" activation markers such as CD71 and CD45RO. 5 Moreover, glutamine is necessary for interleukin-2 production of spleen lymphocytes. 4 Recently an association among glutamine administration, lymphocyte proliferation, and the redox state was shown. Administration of glutamine during lymphocyte cultivation enhanced production of glutathione as measured by flow cytometry. 26 In the current study, administration of LPS produced a marked reduction in glutathione levels in PPs associated with a decrease of B and T cells. A relationship between the lowered glutathione levels and the decrease in lymphocytes can be hypothesized because the administration of BSO, a known inhibitor of glutathione synthesis, also caused a decrease of lymphocytes in the PPs. Interestingly, the oral supply of glutamine prevented the drop of glutathione as well as that of B and T cells. To our knowledge, this is the first time that it has been shown under in vivo conditions that LPS leads to a glutathione deficiency in an immunologic organ and that this can be prevented by pretreatment with glutamine. Previous investigations about glutamine and glutathione metabolism focused mainly on hepatic injury. Hence, it was shown that acetaminophen-evoked hepatic glutathione depletion was prevented when the animals received glutamine supplements. 27 In a similar manner, parenteral nutrition supplemented with alanyl-glutamine preserved hepatic glutathione stores after 5-fluorouracil treatment. 28 These experimental results were confirmed in patients during bone marrow transplantation, when parenteral glutamine infusion preserved hepatic function by maintaining plasma levels of protein C and albumin. 29 These results reveal that glutamine administration in parenteral or oral/enteral form markedly affects glutathione levels in different organs. Because a lowered glutathione state has been shown in pathophysiologic conditions such as intoxication, diabetes, uremia, inflammatory lung injury, coronary disease, and immunodeficiency, 30 parenteral or oral/enteral glutamine supply may support glutathione and cell redox state in certain clinical conditions. Enteral nutrition supplemented with certain key nutrients results in a significant reduction in the risk of developing infectious complications. 31, 32 Of the various substances known to have beneficial effects on immune function, arginine, omega-3 fatty acids, nucleotides, and glutamine are already included in clinical products. Whereas several clinical studies gave evidence that a combination of key nutrients has positive effects on critically ill patients and patients with cancer, only a few investigations were performed with enteral nutrition supplemented with only one key nutrient. Recently, Houdijk et al 8 showed that glutamine-enriched enteral nutrition reduced the frequency of pneumonia, sepsis, and bacteremia in patients with multiple trauma. These results have not been confirmed in critically ill patients. Glutamine-supplemented enteral nutrition proved to reduce hospital costs but did not affect the clinical outcome of these patients. 33 In an experimental investigation, we compared two immune-enhancing diets, one supplemented with glutamine alone and the other supplemented with glutamine, arginine, glycine, and omega-3 fatty acids, on both lymphocyte behavior of PPs and the spleen and on intestinal and splenic glutathione content. This study revealed that glutamine alone was as effective as the mixture of key nutrients in increasing the number of T and B cells in PPs and the spleen; it was even advantageous in stimulating intestinal IgA content. 34 These experimental and clinical results show that glutamine-supplemented enteral nutrition has a measurable immunologic and clinical effect, possibly comparable to that of a mixture of key nutrients.
Until now it has been unclear whether enteral glutamine is metabolized in a different way than parenteral glutamine. In patients undergoing gastric or pancreatic surgery, glutamine-enriched tube feeding and glutamine-enriched parenteral nutrition resulted in similar profiles for most plasma amino acids; however, in patients with intrahepatic portosystemic shunt and liver cirrhosis, enteral glutamine administration caused higher postfeeding hyperammonemia than parenteral glutamine administration. 35 Therefore, the route of glutamine administration is possibly disease-dependent. Many more clinical studies have been performed with glutamine-enriched parenteral nutrition than with enteral-glutamine supplementation, so additional work is needed to prove an advantage of enterally supplied glutamine under different clinical conditions. In summary, our results show that oral glutamine prevents the atrophy of PPs during endotoxemia and prevents the LPS-evoked depletion of glutathione in PPs. Interestingly, BSO, an inhibitor of glutathione synthesis, produces effects similar to those of LPS by reducing the lymphocyte numbers in PPs. Further study must clarify whether LPS reduces glutathione by interfering with the enzymes of glutathione synthesis or whether it simply reduces intracellular glutathione by increasing the formation of oxygen radicals. Moreover, the current study raises the question of whether preoperative oral feeding with glutamine can reduce postoperative immunodepression, and therefore may become a significant component of perioperative therapy.
